# Lajos Pusztai

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lajos-pusztai/

## Facts

| Field | Value |
| --- | --- |
| Citations | 70,151 |
| Field | Breast Cancer Treatment Studies |
| h-index | 115 |
| i10-index | 454 |
| Last Known Institution | Yale Cancer Center |
| OpenAlex ID | https://openalex.org/A5021113979 |
| ORCID iD | https://orcid.org/0000-0001-9632-6686 |
| Works | 1,396 |

## Researcher papers

Showing 12 of 18.

- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple/)
- [Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing](https://scholariq.org/papers/development-and-validation-of-a-clinical-cancer-genomic-profiling-test-based-on/)
- [Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy](https://scholariq.org/papers/measurement-of-residual-breast-cancer-burden-to-predict-survival-after/)
- [Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy](https://scholariq.org/papers/cancer-cell-autonomous-contribution-of-type-i-interferon-signaling-to-the/)
- [The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models](https://scholariq.org/papers/the-microarray-quality-control-maqc-ii-study-of-common-practices-for-the/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](https://scholariq.org/papers/pharmacogenomic-predictor-of-sensitivity-to-preoperative-chemotherapy-with/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer](https://scholariq.org/papers/microtubule-associated-protein-tau-a-marker-of-paclitaxel-sensitivity-in-breast/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [Yale Cancer Center](https://scholariq.org/institutions/yale-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.